ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 512,84
0,32%
DAX
18 772,85
0,50%
Brent Oil
82,585
0,00%
Bitcoin
60 664,17
-0,22%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. C4 Therapeutics Inc (CCCC)

  7. C4 Therapeutics Inc (CCCC) Actualités

CCCC C4 Therapeutics Inc

6,16
-0,64 (-9,41%)
11 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
C4 Therapeutics Inc CCCC NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,64 -9,41% 6,16 06:00:13
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
6,85 6,15 6,935 6,16 6,80
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
08/5/202413:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202413:07EDGAR2Form 8-K - Current report
08/5/202413:00GLOBEC4 Therapeutics Reports First Quarter 2024 Financial Results..
29/4/202422:01GLOBEC4 Therapeutics Announces Inducement Grant Under Nasdaq..
09/4/202413:00GLOBEC4 Therapeutics to Participate in the Stifel 2024 Targeted..
08/4/202414:00GLOBEC4 Therapeutics Presents New Preclinical Data for CFT1946..
09/3/202401:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/3/202401:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/3/202401:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/3/202401:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/3/202401:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202422:10EDGAR2Form 8-K - Current report
05/3/202422:30GLOBEC4 Therapeutics to Present New Preclinical Data on Highly..
04/3/202413:05EDGAR2Form 8-K - Current report
04/3/202413:00GLOBEC4 Therapeutics Announces Strategic Discovery Research..
22/2/202415:01EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/2/202413:20EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202413:15EDGAR2Form 8-K - Current report
22/2/202413:00GLOBEC4 Therapeutics Reports Fourth Quarter and Full Year 2023..
15/2/202423:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202423:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202423:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202415:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202416:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
02/2/202415:34EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/1/202422:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
11/1/202413:05EDGAR2Form 8-K - Current report
09/1/202422:06EDGAR2Form 8-K - Current report
09/1/202422:01GLOBEC4 Therapeutics Announces 2024 Priorities and Extended Cash..
04/1/202422:01GLOBEC4 Therapeutics Announces Closing of $25 Million Equity..
04/1/202413:00GLOBEC4 Therapeutics to Present at the 42nd Annual J.P. Morgan..
03/1/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202322:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/12/202322:28EDGAR2Form 8-K - Current report
12/12/202322:01GLOBEC4 Therapeutics Announces Positive Data from CFT7455 Phase 1..
12/12/202315:15APSBiotech Catches Major Premarket Bid
12/12/202313:15EDGAR2Form 8-K - Current report
12/12/202313:00GLOBEC4 Therapeutics Announces License and Research Collaboration..
28/11/202313:00GLOBEC4 Therapeutics to Host Webcast to Present New Dose..
20/11/202313:05EDGAR2Form 8-K - Current report
20/11/202313:00GLOBEC4 Therapeutics Strengthens Board of Directors with Owen..
13/11/202322:55EDGAR2Form SC 13G - Statement of acquisition of beneficial..
01/11/202312:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202312:18EDGAR2Form 8-K - Current report
01/11/202312:00GLOBEC4 Therapeutics Reports Third Quarter 2023 Financial Results..
11/10/202313:00GLOBEC4 Therapeutics Announces Upcoming Data Presentations for..
03/10/202322:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
CCCC
C4 Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés